Source comparison
Receptor Selectivity: Melanotan-2 vs Melanotan-1 and Setmelanotide
Melanotan-1 (afamelanotide) and setmelanotide offer instructive contrasts. Afamelanotide, approved in Europe and the U.S. for erythropoietic protoporphyria (EPP), demonstrates strong MC1R selectivity. Approximately 10–20× higher affinity for MC1R than MC4R. Th
This comparison does not assign a generated winner or score.
- Melanotan-1 (afamelanotide) and setmelanotide offer instructive contrasts. Afamelanotide, approved in Europe and the U.S. for erythropoietic protoporphyria (EPP), demonstrates strong MC1R selectivity. Approximately 10–20× higher affinity for MC1R than MC4R. That selectivity produces melanogenesis with minimal appetite or erectile effects, which is why afamelanotide's adverse event profile centers on injection site reactions and mild nausea rather than the broader systemic effects seen with MT2. Clinical trials for EPP reported melanogenesis sufficient to raise minimal erythemal dose (MED) by 2.5–4× without significant weight loss or sexual side effects.
- Setmelanotide (marketed as Imcivree) represents the opposite design philosophy: extreme MC4R selectivity for obesity treatment. Setmelanotide's binding affinity favors MC4R over MC3R by approximately 80-fold and over MC1R by 200-fold. That selectivity isolates appetite suppression and produces clinically meaningful weight loss (approximately 10–15% in patients with POMC or LEPR deficiency obesity) while minimizing pigmentation changes. Adverse events still include nausea (54% in pivotal trials), because MC4R activation in the brainstem can't be avoided, but spontaneous erections and flushing are far less common than with MT2.
- Melanotan-2 non-selective MCR agonism occupies the middle ground. Broad receptor activation with no dominant selectivity. That makes it a poor candidate for single-indication therapeutics but a valuable research tool for studying MCR cross-talk and overlapping physiology. Real Peptides also offers Melanotan 1, which provides a more MC1R-selective profile for researchers comparing receptor-specific responses.
- Melanotan-1 (afamelanotide)
- High (10–20× vs MC4R)
- Low
- Photoprotection, melanogenesis isolation
- Injection site reactions, mild nausea, minimal appetite/sexual effects
- Melanotan-2
- None (promiscuous)
- Multi-receptor MCR research, cross-pathway studies
- Nausea, flushing, spontaneous erections, appetite suppression, pigmentation
- Setmelanotide
- Minimal
- Very high (80× vs MC3R)
- MC4R-driven obesity, appetite pathway isolation
- Nausea, hyperpigmentation at high doses, minimal flushing/erectile effects
- The EC50 data clarify the distinction. Melanotan-2's EC50 values across MC1R, MC3R, and MC4R cluster between 0.3–1.2 nM. A narrow range indicating roughly equivalent receptor activation at physiological concentrations. Setmelanotide's EC50 at MC4R is approximately 0.27 nM, but its EC50 at MC3R exceeds 20 nM. A 74-fold difference that prevents MC3R activation at therapeutic doses. That selectivity is structural, built into setmelanotide's peptide backbone through amino acid substitutions that sterically favor MC4R binding pockets.
- Melanotan-2 lacks those modifications. Its structure closely mirrors α-MSH, the endogenous ligand that activates all five MCR subtypes during normal physiology. The research advantage: MT2 replicates the body's own non-selective signaling, making it suitable for studying how melanocortin pathways interact when activated simultaneously. The clinical disadvantage: you can't prescribe MT2 for one indication without triggering the others.